Conferences - Results from #10900

Viewing 10901-10920 of 11879 articles

SUFU WM 2014 - Laser vaporization of the prostate with the 180-W XPS-Greenlight laser in patients with large prostates - Session Highlights

SUFU WM 2014 - Voiding symptoms and treatments after robotic-assisted prolapse surgery - Session Highlights

SUFU WM 2014 - Mechanism of action of the midurethral sling: A critical appraisal - Session Highlights

24th Int'l Prostate Cancer Update: Poster - PSA kinetics following robotic stereotactic body radiotherapy for localized prostate cancer

24th Int'l Prostate Cancer Update: Poster - Finding occult prostatic cancer: The value of transperineal mapping biopsies and epigenetic assays

24th Int'l Prostate Cancer Update: Poster - Hematologic Safety of radium-223 dichloride (radium-223) in castration-resistant prostate cancer patients with bone metastases from the phase 3 ALSYMPCA trial: Baseline prognostic factor subgroup analysis

24th Int'l Prostate Cancer Update: Poster - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

24th Int'l Prostate Cancer Update: Poster - Intermittent androgen deprivation with the gonadotrophin−releasing hormone (GnRH) antagonist degarelix

24th Int'l Prostate Cancer Update: Abstract - Early clinical experience with the 17-gene Genomic Prostate Score for newly diagnosed prostate cancer

24th Int'l Prostate Cancer Update: Abstract - Long-term results of focal therapy for prostate cancer

24th Int'l Prostate Cancer Update: Abstract - Efficacy and safety of radium-223 dichloride (radium-223) in patients who did or did not receive prior docetaxel in the phase 3 ALSYMPCA trial

24th Int'l Prostate Cancer Update: Abstract - Role of optical spectroscopy in the diagnosis of prostatic cancer

24th Int'l Prostate Cancer Update: Abstract - Intermittent androgen deprivation with the gonadotrophin−releasing hormone (GnRH) antagonist degarelix

24th Int'l Prostate Cancer Update: Abstract - Real-world corticosteroid utilization in prostate cancer patients treated with two new oral agents

24th Int'l Prostate Cancer Update: Abstract - Prostate cancer patients demonstrate adherence to medication while on abiraterone acetate (AA) therapy

24th Int'l Prostate Cancer Update: Abstract - Unsuspected metastases found during screening for a trial of patients with non-metastatic castration resistant prostate cancer

24th Int'l Prostate Cancer Update: Abstract - Cost considerations for new oral therapies for patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with docetaxel

24th Int'l Prostate Cancer Update: Abstract - Effect of a 22-marker genomic classifier assay on adjuvant radiation therapy recommendations in patients with high-risk prostate cancer

24th Int'l Prostate Cancer Update: Abstract - Robotic prostatectomy and the ambulatory surgery center – A transition to outpatient care

24th Int'l Prostate Cancer Update: Abstract - Hematologic Safety of radium-223 dichloride (radium-223) in castration-resistant prostate cancer patients with bone metastases from the phase 3 ALSYMPCA trial: Baseline prognostic factor subgroup analysis

541
542
543
544
545
546
547
548
549
550